Astragalus
A telomere headline built on a derivative compound, sponsor studies, and a surrogate endpoint.
D+
Evidence grade
D
Worth it
$12-25/month
Typical cost
DoseProducts provide 500 to 3,000 mg/day of root extract or powder, standardized inconsistently to polysaccharides or astragalosides. TA-65 is dosed in milligrams of the purified derivative, an entirely different exposure from root products; comparing them on a label is the category's standard sleight of hand.
BasisAstragalus has centuries of traditional use, a fashionable telomere narrative, and a human evidence file made of small, interested, surrogate-endpoint studies and bias-prone meta-analyses.
Astragalus is a traditional Chinese medicine root (Astragalus membranaceus) sold for immune support and, in longevity circles, for telomere maintenance via its derivative cycloastragenol. We grade Astragalus D+ on evidence and D for worth-it at about $12-25 per month.
What it does
Astragalus is a traditional Chinese medicine root (Astragalus membranaceus) sold for immune support and, in longevity circles, for telomere maintenance via its derivative cycloastragenol. The root, the derivative, and the claims are three different things, and this record keeps them separate.
What the research says
The telomerase story: a derivative compound showed telomere effects in sponsor-run human studies
Evidence: weak. Cycloastragenol (sold as TA-65), a molecule derived from astragalus, was reported to lengthen telomeres in immune cells in a sponsored study program (Harley 2011; a small randomized study, Salvador 2016, found shifts in immune cell measures). Telomere length in blood cells is a surrogate with no demonstrated line to lifespan or healthspan outcomes, the studies are small and commercially interested, and ordinary astragalus root extract is not the studied compound at the studied exposure. Three gaps separate the marketing from the data.
Immune and adjunct claims rest on low-quality trial literatures
Evidence: weak. Chinese meta-analyses of astragalus preparations alongside chemotherapy report quality-of-life and response benefits, with high bias risk throughout. Small trials for fatigue and respiratory infections exist without replication. Nothing in the human file survives a strict quality screen, which is the screen this library applies.
Astragalus has centuries of traditional use, a fashionable telomere narrative, and a human evidence file made of small, interested, surrogate-endpoint studies and bias-prone meta-analyses. Traditional use is a reason to study a plant; it is not itself study results. D+ reflects genuine scientific interest around a molecule, with no outcome evidence for the products actually sold.
Is it worth it?
Evidence (D+) sits far below the leaderboard floor, so the worth-it grade is capped at C+; the derived value lands at D. About $18 a month at common doses. Derived from the October 2026 worth-it model.
Typical cost
$12-25/month
Common form, not a brand recommendation
Dosage context established
Products provide 500 to 3,000 mg/day of root extract or powder, standardized inconsistently to polysaccharides or astragalosides. TA-65 is dosed in milligrams of the purified derivative, an entirely different exposure from root products; comparing them on a label is the category's standard sleight of hand.
Worth-it leaderboard
Astragalus sits outside the worth-it top 20.
Astragalus sits outside the current top 20 on the gated leaderboard. The leaders below clear an evidence floor of B- before price counts at all, so cheap alone never earns a rank.
- 1AWorth itCreatine evidence A-~$5-10/mo
- 2AWorth itCaffeine evidence B+~$5-10/mo
- 3AWorth itVitamin D evidence B~$5-8/mo
See the full worth-it leaderboard →
When the evidence moves a grade, this ranking moves with it. Thursday is where you hear it first.
Safety notes
Generally well tolerated. Because it stimulates immune activity in preclinical work, people with autoimmune conditions and anyone on immunosuppressants (transplant medicine above all) should not use it without their specialist; that caution is theoretical but the stakes are asymmetric. Pregnancy data are absent. Quality varies widely across root products.
Longevity Lab Report
Astragalus news. Graded when it happens.
The grade on this page stays free. The email carries the news on astragalus: expert moves, dose changes, and what is working, in plain English every Thursday.
Changelog
Last updated 2026-10-23
- 2026-10-23|Graded from the TA-65 telomere studies and the adjunct-therapy meta-analytic literature. The record separates the root (what is sold) from the derivative (what was studied) and the surrogate (what was measured) from the outcome (what is claimed).
- 2026-10-23|Not listed under longevity or any other goal: the graded findings are surrogate-level telomere measures and low-quality adjunct data, and goal tags follow outcome-grade findings.
The week's longevity and biohacking news.
This grade for Astragalus rests on the record above. When a new result changes that record, the grade changes with it, and the Thursday email is where the change lands first: the week's longevity and biohacking news, in plain English, linked back to the reasoning on this page.
The week's longevity and biohacking news. Every story graded against the evidence. Free. Unsubscribe anytime.
Every grade follows a published rubric, and sponsors never change one. When the evidence moves a grade, Thursday is where you hear it first, before you renew a stack that stopped earning its cost.